查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000707

疫苗佐剂市场：按给药途径、製剂、疫苗类型和最终用户分類的全球市场预测 – 2026–2032 年

Vaccine Adjuvants Market by Delivery Route, Formulation, Vaccine Category, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，疫苗佐剂市值将达到 9.4788 亿美元，到 2026 年将成长至 10.1993 亿美元，到 2032 年将达到 16.6517 亿美元，年复合成长率为 8.38%。

主要市场统计数据
基准年 2025 9.4788亿美元
预计年份：2026年 1,019,930,000 美元
预测年份 2032 1,665,170,000 美元
复合年增长率 (%) 8.38%

这本入门书籍全面说明了各种疫苗技术和佐剂在临床环境中的科学背景、监管框架和战略重要性。

疫苗佐剂已从单纯的添加剂发展成为对疫苗效力、免疫反应持久性和分发模式具有重大影响的策略要素。近年来，製剂科学、给药途径创新和监管要求的相互作用，使得佐剂的选择从下游製剂决策提升为早期设计阶段的关键参数。随着相关人员应对日益复杂的生物学挑战，从新一代mRNA平台到复杂的重组构建体，佐剂既是科学优势，也是商业性差异化的关键因素。

科学突破、监管现代化和商业性整合的整合如何从根本上改变疫苗佐剂的研发和应用动态。

疫苗佐剂领域正经历一系列变革，其驱动力包括技术进步、监管现代化以及相关人员期望的转变。从科学角度来看，人们对核酸疫苗的兴趣激增，促使人们研究能够增强抗原呈现和细胞免疫的佐剂，从而推动了对新型脂质和颗粒载体的研发投入。同时，鼻腔和口服给药途径的创新也迫使製剂研发人员重新思考稳定性和黏膜免疫抗原性，而不只依赖全身注射的特性。

2025 年美国关税措施对辅助供应链中采购、製造和策略采购的重组的营运、供应链和监管影响。

美国2025年生效的关税政策对疫苗佐剂生态系统内的供应链、筹资策略和跨境生产决策产生了连锁反应。依赖进口原料、特殊脂质和关键颗粒添加剂的公司立即面临进口后原物料成本和采购前置作业时间的压力。因此，采购团队加快了供应商资格合格流程，探索了近岸替代方案，并增加了库存缓衝，以确保临床试验进度并履行商业性承诺。

高解析度細項分析，将递送途径、配方类型、最终用户环境和疫苗类别与技术和商业性决策标准相匹配。

基于细分市场的观点揭示了指导佐剂领域开发、商业化和应用方案的实用差异化因素。临床目标因给药途径的不同而显着差异。肌注仍然是全身免疫和高效临床路径的既定标准。鼻内给药着重于黏膜免疫，并可能改变製剂稳定性要求。口服给药强调可扩展性和患者耐受性，但需要确保其抗酸酶稳定性。皮下给药涉及特定的剂量和耐受性限制，这些限制会影响辅料的选择。

区域战略观点：揭示美洲、欧洲、中东和非洲以及亚太地区如何对佐剂策略施加不同的政策、製造和采用压力。

区域趋势对佐剂研究重点、生产策略和市场准入有显着影响。在美洲，私部门的创新中心和活跃的创业投资持续加速转化研究和早期临床计画的推进，而先进的生物製造能力则支持已达到监管里程碑的计画快速扩大规模。此外，该地区的政策框架鼓励官民合作关係，并为国内生产提供奖励，从而影响製造商和开发商的投资决策。

透过独特的技术、服务产品和在佐剂生态系统中整合的製造能力，使公司脱颖而出的策略行动和伙伴关係模式。

疫苗佐剂生态系统中的主要企业正采用多种差异化策略组合来确保竞争优势。一些企业优先发展专有製剂平台和专利化学技术，大力投资于作用机制研究和基于生物标记的差异化，以建立可持续的智慧财产权竞争优势。另一些企业则采用服务主导模式，为追求速度和监管认可的疫苗研发企业提供製剂开发、分析等效性评估和契约製造服务。

优先考虑经营团队，以增强供应韧性，简化监管合规流程，并加速辅助创新在整个价值链中的临床应用。

为了将洞见转化为有效行动，产业领导者应采取一系列优先措施，以增强韧性并加速临床应用。首先，实现关键原料来源多元化，并对高风险添加剂和脂质采取多源采购策略，以降低关税和地缘政治衝击的影响。同时，投资于区域製造伙伴关係和技术转让，以建立冗余机制，并维持快速推进临床应用。

一种透明且可重复的调查方法，它整合了与专家的初步访谈、文献整合、专利和监管分析以及可靠的交叉检验技术。

本报告提出的结论和建议是基于严谨的调查方法，该方法结合了第一手资料和第二手资料，并透过与专家的对话检验。第一手资料研究包括与临床研究人员、药物科学家、监管专家和生产管理人员进行结构化访谈和共识研讨会，以确定实际应用中的限制和策略重点。第二手资料研究则利用同侪审查文献、临床试验註册资讯、专利资料库和监管指导文件，梳理科学进度和监管先例。

策略性地整合关键见解，突出可操作的优先事项，以协调佐剂开发中的科学创新、生产韧性和监管合作。

总之，疫苗佐剂如今在疫苗研发中扮演核心策略角色，影响着免疫抗原性、给药物流和商业性差异化。製剂设计和给药途径的技术进步，加上不断变化的监管预期和供应链的脆弱性，既为研发人员、生产商和医疗保健系统带来了机会，也带来了营运上的挑战。那些能够将科学严谨性、生产柔软性和积极的监管合作相结合的相关人员，将更有能力将佐剂创新转化为安全、有效且广泛可用的疫苗。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依给药途径分類的疫苗佐剂市场

  • 肌肉内部
  • 鼻腔
  • 口服
  • 皮下

第九章：按製剂分類的疫苗佐剂市场

  • 乳液
  • ISCOM
  • 脂质体
  • 细颗粒物
  • 皂素复合物

第十章：以疫苗类型分類的疫苗佐剂市场

  • 细菌疫苗
  • DNA疫苗
  • 药效疫苗
  • 重组疫苗
  • 病毒疫苗

第十一章：疫苗佐剂市场：依最终用户划分

  • 诊所
    • 门诊部
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院
  • 研究机构
    • 政府附属组织
    • 私人研究机构

第十二章：疫苗佐剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：疫苗佐剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：疫苗佐剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国疫苗佐剂市场

第十六章：中国疫苗佐剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agenus, Inc.
  • Aphios Corporation
  • Bioveta, AS
  • Croda International PLC
  • CSL Limited
  • Dynavax Technologies Corporation
  • GlaxoSmithKline PLC
  • Hayashibara Co. Ltd.
  • InvivoGen
  • Merck KGaA
  • MVP Laboratories, Inc.
  • Novavax, Inc.
  • OZ Biosciences
  • Pacific GeneTech Limited
  • Seppic SA
  • SHIONOGI & Co., Ltd.
  • SPI Pharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vaxine Pty Ltd.
  • Zoetis Services LLC
Product Code: MRR-02026C4C8667

The Vaccine Adjuvants Market was valued at USD 947.88 million in 2025 and is projected to grow to USD 1,019.93 million in 2026, with a CAGR of 8.38%, reaching USD 1,665.17 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 947.88 million
Estimated Year [2026] USD 1,019.93 million
Forecast Year [2032] USD 1,665.17 million
CAGR (%) 8.38%

A comprehensive primer that contextualizes the science, regulatory boundaries, and strategic importance of adjuvants across diverse vaccine technologies and clinical settings

Vaccine adjuvants have evolved from ancillary additives into strategic enablers that materially influence vaccine efficacy, durability of immune response, and distribution models. In recent years, the interplay between formulation science, delivery route innovation, and regulatory expectations has elevated adjuvant selection from a downstream formulation decision to a critical early-stage design parameter. As stakeholders navigate increasingly complex biological challenges-from next-generation mRNA platforms to complex recombinant constructs-adjuvants are both a scientific lever and a commercial differentiator.

This introductory analysis synthesizes core scientific principles, key development inflection points, and regulatory touchstones that shape adjuvant advancement. It highlights how delivery route choices such as intramuscular, intranasal, oral, and subcutaneous administration influence formulation constraints and clinical endpoints. Moreover, it underscores how formulation classes including emulsions, immune-stimulating complexes, liposomes, particulate systems, and saponin complexes present distinct manufacturability and stability profiles that directly affect downstream decisions.

Finally, this primer situates end user considerations across clinics, hospitals, and research institutes, and examines how vaccine categories spanning bacterial, DNA, mRNA, recombinant, and viral platforms intersect with adjuvant strategy. By grounding the discussion in these foundational elements, the reader obtains a coherent frame to assess subsequent strategic and operational implications.

How converging scientific breakthroughs, regulatory modernization, and commercial integration are fundamentally reshaping vaccine adjuvant development and adoption dynamics

The landscape for vaccine adjuvants is undergoing a series of transformative shifts driven by technological advances, regulatory modernization, and changing stakeholder expectations. At a scientific level, the surge of interest in nucleic acid vaccines has necessitated adjuvant research that augments both antigen presentation and cellular immunity, prompting renewed investment into novel lipid and particulate carriers. Concurrently, innovations in intranasal and oral delivery routes are forcing formulators to rethink stability and mucosal immunogenicity rather than relying solely on systemic injection profiles.

On the regulatory front, agencies are clarifying pathways for adjuvant-containing constructs while simultaneously demanding robust justification for safety and mechanism of action. This regulatory tightening encourages earlier and deeper dialogue between developers and regulators, and increasingly rewards structured preclinical immunoprofiling and translational biomarkers. Commercially, the advent of platform technologies has shifted value creation toward integrated solutions where adjuvant expertise is bundled with antigen design and delivery systems, motivating strategic alliances between specialty adjuvant developers, vaccine innovators, and contract manufacturers.

Taken together, these shifts accelerate the consolidation of technical capabilities, raise the bar for evidentiary standards, and create differentiated pathways to clinical adoption. As a result, organizations that align scientific investment with regulatory foresight and supply chain resilience will gain decisive advantages in a market defined by both rapid innovation and heightened scrutiny.

Operational, supply chain, and regulatory ramifications of the 2025 United States tariff measures reshaping procurement, manufacturing, and strategic sourcing in the adjuvant supply chain

The introduction of United States tariffs in 2025 has produced a ripple effect across supply chains, procurement strategies, and cross-border manufacturing decisions within the vaccine adjuvant ecosystem. Companies dependent on imported raw materials, specialized lipids, and key particulate excipients experienced immediate pressure on landed input costs and procurement lead times. In turn, procurement teams accelerated supplier qualification processes, sought near-shore alternatives, and increased inventory buffers to preserve clinical timelines and commercial commitments.

Beyond direct cost effects, tariffs reinforced strategic reassessments about geographic concentration of production. Developers and contract manufacturers began evaluating the trade-offs between onshore manufacturing investments and the economics of globalized supply. Regulatory considerations compounded these operational shifts, since any change in source materials or manufacturing sites often triggers comparability studies and supplementary regulatory filings-activities that consume both time and scientific resources.

Importantly, the tariffs also highlighted the structural interdependencies between raw material sourcing, intellectual property overlays, and export controls for advanced adjuvant platforms. Stakeholders responded by diversifying supplier networks, investing in multi-sourcing strategies for critical excipients, and accelerating technology transfers where feasible. Ultimately, the cumulative impact extended beyond immediate cost adjustments, compelling a strategic reorientation toward supply chain resilience and manufacturing flexibility that will influence program design and partnership choices over the medium term.

High-resolution segmentation analysis that aligns delivery routes, formulation types, end-user environments, and vaccine categories with technical and commercial decision criteria

A segmentation-driven view surfaces actionable differentiators that inform development, commercialization, and deployment choices across the adjuvant landscape. When considering delivery route, the clinical objectives vary materially: intramuscular administration remains the established standard for systemic immunity and streamlined clinical pathways; intranasal approaches prioritize mucosal immunity and can alter formulation stability demands; oral delivery emphasizes scalability and patient acceptability but requires acid- and enzyme-stability engineering; subcutaneous delivery presents distinct volume and tolerability constraints that influence excipient selection.

Formulation segmentation reveals trade-offs among technology classes. Emulsions offer proven potency with recognizable manufacturing footprints, while immune-stimulating complexes (ISCOMs) provide targeted antigen presentation advantages but carry more complex assembly and characterization requirements. Liposomes deliver versatility for both small and large antigens and dovetail with nucleic acid modalities, whereas particulate systems enable depot effects and sustained release. Saponin complexes deliver robust adjuvant activity with specific safety and sourcing considerations that must be proactively managed.

End user segmentation influences adoption pathways. Clinics, including outpatient and specialty settings, demand low-complexity administration and strong cold-chain resilience. Hospitals, both private and public, prioritize scalable stock management and integration with immunization schedules. Research institutes, spanning government bodies and private laboratories, drive early innovation and validation work that feeds commercialization pipelines. Finally, vaccine category segmentation-covering bacterial, DNA, mRNA, recombinant, and viral vaccines-dictates differential immunological endpoints and regulatory data expectations, requiring tailored adjuvant strategies that align scientific mechanism with clinical objectives.

A regional strategic lens revealing how the Americas, Europe Middle East & Africa, and Asia-Pacific exert distinct policy, manufacturing, and adoption pressures on adjuvant strategies

Regional dynamics exert a powerful influence over research prioritization, manufacturing strategy, and market access for adjuvants. In the Americas, private sector innovation hubs and strong venture capital activity continue to accelerate translational research and early clinical programs, while advanced biomanufacturing capacity supports rapid scale-up for programs that clear regulatory milestones. Policy frameworks in this region also encourage public-private partnerships and incentives for domestic production, which shape investment calculus for manufacturers and developers.

In Europe, Middle East & Africa, regulatory harmonization efforts and collaborative procurement mechanisms drive different adoption timelines and evidence requirements. Europe's dense regulatory expertise and established contract manufacturing ecosystems support complex formulation development, whereas countries across the Middle East and Africa emphasize readiness, supply security, and local manufacturing partnerships to improve access. These heterogeneous priorities require tailored engagement strategies by developers that respect regional regulatory expectations and procurement practices.

Asia-Pacific displays pronounced diversity between advanced biopharma markets and rapidly developing ecosystems. Regional supply chain strengths, particularly in specialized excipient production and large-scale fill-finish operations, create opportunities for vertical integration and cost-efficient manufacturing. Simultaneously, growing domestic R&D capabilities and strategic government investments in biotech infrastructure are creating new centers of excellence that accelerate adoption for novel adjuvant technologies. Collectively, these regional patterns inform strategic decisions about partnership models, localization, and regulatory engagement.

Strategic corporate behaviors and partnership models that differentiate firms through proprietary science, service offerings, and integrated manufacturing capabilities within the adjuvant ecosystem

Leading organizations in the vaccine adjuvant ecosystem are deploying a mix of differentiated strategies to secure competitive advantage. Some firms prioritize proprietary formulation platforms and patent-protected chemistries to create durable intellectual property moats, investing heavily in mechanism-of-action studies and biomarker-driven differentiation. Others adopt a services-led model, offering formulation development, analytical comparability, and contract manufacturing capabilities that cater to vaccine developers seeking speed and regulatory confidence.

Strategic partnerships are another central theme: alliances between specialized adjuvant developers and large vaccine manufacturers accelerate clinical translation and broaden access to late-stage development expertise. Contract development and manufacturing organizations have also expanded capabilities to support complex adjuvant formulations, including lipid systems and particulate assemblies, which reduces technical risk for sponsors. Additionally, technology transfers and licensing agreements play an outsized role in enabling geographic manufacturing scale-up while preserving core proprietary elements.

Finally, several players are integrating digital and data-driven approaches to improve formulation screening, stability modeling, and supply chain visibility. By combining high-throughput experimental platforms with advanced analytics, companies are shortening iteration cycles and improving predictability in development outcomes. Together, these corporate behaviors illustrate a competitive landscape that values both deep technical differentiation and pragmatic operational excellence.

Priority actions for executives to bolster supply resilience, streamline regulatory alignment, and accelerate clinical translation of adjuvant innovations across the value chain

To translate insight into effective action, industry leaders should adopt a prioritized set of measures that strengthen resilience and accelerate clinical translation. First, diversify critical raw material sources and pursue multi-sourcing strategies for high-risk excipients and lipids to reduce exposure to tariff and geopolitical shocks. Simultaneously, invest in regional manufacturing partnerships and technology transfers that preserve speed to clinic while building redundancy.

Second, align early-stage development with regulatory expectations through proactive engagement. Incorporate mechanism-of-action studies, translational biomarkers, and robust comparability plans into development programs to anticipate data requirements and shorten review cycles. Third, optimize formulation strategies by matching adjuvant class to delivery route and vaccine category: select systems that balance immunogenic potency with manufacturability and stability under realistic distribution scenarios.

Fourth, pursue collaborative models that blend proprietary innovation with service capacity-partner with contract developers and academic centers to de-risk scale-up and leverage external manufacturing expertise. Finally, embed data-centric capabilities across R&D and supply chain functions to improve predictability, from in silico screening to shelf-life forecasting. Taken together, these recommended actions create a pragmatic roadmap for organizations seeking to convert scientific promise into reliable clinical and commercial outcomes.

A transparent, reproducible research methodology integrating expert primary interviews, literature synthesis, patent and regulatory analysis, and robust cross-validation practices

The conclusions and recommendations presented in this report rest upon a rigorous methodology combining primary and secondary evidence streams validated through expert engagement. Primary research included structured interviews and consensus workshops with clinical investigators, formulation scientists, regulatory affairs specialists, and manufacturing leaders to surface real-world constraints and strategic priorities. Secondary research relied on peer-reviewed literature, clinical trial registries, patent databases, and regulatory guidance documents to map scientific trajectories and regulatory precedents.

Analytical techniques encompassed qualitative thematic analysis, cross-validation of technical assumptions, and synthesis of manufacturing and supply chain risk indicators. Where comparability or generalizability was required, triangulation across independent sources ensured robustness of interpretation. Quality assurance steps included iterative review cycles with subject-matter experts, reconciliation of conflicting evidence, and sensitivity checks on key technical inferences.

The methodology intentionally emphasized transparency and reproducibility: all sources and analytical decisions are cataloged in the methodological annex, and key uncertainties are explicitly called out to inform risk-aware decision-making. This approach enabled the development of actionable insights that reflect both the current scientific state and operational realities facing adjuvant developers and their partners.

Strategic synthesis of core findings emphasizing actionable priorities to align scientific innovation, manufacturing resilience, and regulatory engagement in adjuvant development

In synthesis, vaccine adjuvants now occupy a central strategic role in vaccine development, influencing immunogenicity, delivery logistics, and commercial differentiation. Technological advances in formulation design and delivery routes, coupled with evolving regulatory expectations and supply chain sensitivities, create both opportunities and operational complexities for developers, manufacturers, and health systems. Stakeholders that integrate scientific rigor, manufacturing flexibility, and proactive regulatory engagement will be best positioned to translate adjuvant innovations into safe, effective, and widely adoptable vaccines.

Near-term priorities include securing resilient supply chains, aligning early development programs with regulatory evidence expectations, and selecting formulation-delivery combinations that reflect end-user realities across clinics, hospitals, and research institutions. At the same time, regional dynamics and tariff-influenced sourcing strategies necessitate careful assessment of manufacturing location, partnership models, and inventory practices.

Ultimately, the path forward requires pragmatic collaboration across industry, government, and academic sectors to balance innovation with access. By adopting the strategic actions outlined in this analysis, organizations can convert scientific potential into durable public health impact while managing financial and operational risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Adjuvants Market, by Delivery Route

  • 8.1. Intramuscular
  • 8.2. Intranasal
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Vaccine Adjuvants Market, by Formulation

  • 9.1. Emulsions
  • 9.2. ISCOMs
  • 9.3. Liposomes
  • 9.4. Particulates
  • 9.5. Saponin Complexes

10. Vaccine Adjuvants Market, by Vaccine Category

  • 10.1. Bacterial Vaccines
  • 10.2. DNA Vaccines
  • 10.3. mRNA Vaccines
  • 10.4. Recombinant Vaccines
  • 10.5. Viral Vaccines

11. Vaccine Adjuvants Market, by End User

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
    • 11.3.1. Government Institutes
    • 11.3.2. Private Laboratories

12. Vaccine Adjuvants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Adjuvants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Adjuvants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vaccine Adjuvants Market

16. China Vaccine Adjuvants Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agenus, Inc.
  • 17.6. Aphios Corporation
  • 17.7. Bioveta, A.S.
  • 17.8. Croda International PLC
  • 17.9. CSL Limited
  • 17.10. Dynavax Technologies Corporation
  • 17.11. GlaxoSmithKline PLC
  • 17.12. Hayashibara Co. Ltd.
  • 17.13. InvivoGen
  • 17.14. Merck KGaA
  • 17.15. MVP Laboratories, Inc.
  • 17.16. Novavax, Inc.
  • 17.17. OZ Biosciences
  • 17.18. Pacific GeneTech Limited
  • 17.19. Seppic S.A.
  • 17.20. SHIONOGI & Co., Ltd.
  • 17.21. SPI Pharma, Inc.
  • 17.22. Takeda Pharmaceutical Company Limited
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Vaxine Pty Ltd.
  • 17.25. Zoetis Services LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ISCOMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ISCOMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ISCOMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SAPONIN COMPLEXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SAPONIN COMPLEXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SAPONIN COMPLEXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY BACTERIAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY BACTERIAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VIRAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VIRAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GCC VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. NATO VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)